Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 16/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiaramide SCHEMBL25172 | 1.00 | NPY5R (0.58) | NPY5RTMEM97GAATSHRNPSR1 | |
| Tiaramide SCHEMBL181916 | 0.99 | NPY5R (0.58) | NPY5RTMEM97GAATSHRNPSR1 | |
| Tiaramide SCHEMBL29379184 | 0.99 | NPY5R (0.58) | NPY5RTMEM97GAATSHRNPSR1 | |
| SCHEMBL13696444 | 0.90 | NPY5R (0.61) | NPY5RTMEM97GAATSHRNPSR1 | |
| SCHEMBL8894950 | 0.89 | TMEM97 (0.58) | NPY5RTMEM97GAATSHRNPSR1 | |
| SCHEMBL11308376 | 0.88 | TMEM97 (0.57) | NPY5RTMEM97TSHR | |
| SCHEMBL11440143 | 0.88 | TMEM97 (0.47) | NPY5RTMEM97GAATSHRNPSR1 | |
| SCHEMBL11406400 | 0.88 | NPY5R (0.47) | NPY5RTMEM97 | |
| SCHEMBL11408981 | 0.86 | NPY5R (0.57) | NPY5RTMEM97GAATSHRNPSR1 | |
| SCHEMBL8902235 | 0.86 | NPY5R (0.56) | NPY5RTMEM97GAATSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126138-B1 | AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS | INVOX BELGIUM NV (BE) | 2024-10-16 | — | — | EP | claimed |
| EP-3829643-B1 | SYNERGISTICALLY COOPERATIVE COMPOSITIONS USEFUL FOR SOFT TISSUE AUGMENTATION, DRUG DELIVERY AND RELATED FIELDS | ALTERGON SA (CH) | 2023-08-30 | — | — | EP | claimed |
| EP-4126138-A1 | AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS | Softhale NV (BE) | 2023-02-08 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-12629484-B2 | High pressure inhalation device | INVOX BELGIUM NV (BE) | 2026-05-19 | — | — | US | disclosed |
| US-12576218-B2 | Valve | INVOX BELGIUM NV (BE) | 2026-03-17 | — | — | US | disclosed |
| US-12569629-B2 | Inhalation device system | INVOX BELGIUM NV (BE) | 2026-03-10 | — | — | US | disclosed |
| EP-4275725-B1 | IMPROVED INHALATION DEVICE | INVOX BELGIUM NV (BE) | 2025-12-10 | — | — | EP | disclosed |
| US-12478748-B2 | Aerosol delivery of at least two liquid compositions | INVOX BELGIUM NV (BE) | 2025-11-25 | — | — | US | disclosed |
| EP-4633823-A1 | MICROSTRUCTURED NOZZLE | invoX Belgium NV (BE) | 2025-10-22 | — | — | EP | disclosed |
| US-20250152860-A1 | INHALATION DEVICE | INVOX BELGIUM NV (BE) | 2025-05-15 | — | — | US | disclosed |
| CN-119896780-A | Improved valve | 索芙特海尔公司 | 2025-04-29 | — | — | CN | disclosed |
| EP-4126134-A1 | INHALATION DEVICE SYSTEM | Softhale NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| EP-4126138-A1 | AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS | Softhale NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023001750-A1 | INHALATION DEVICE SYSTEM WITH A COUNTING AND BLOCKING ASSEMBLY | SOFTHALE NV (BE) | 2023-01-26 | — | — | WO | disclosed |
| CN-115485000-A | Aerosol delivery of at least two liquid compositions | 索芙特海尔公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115087665-A | Engineered platelets for targeted delivery of therapeutic agents | JPV01有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220143328-A1 | IMPROVED VALVE | INVOX BELGIUM NV (BE) | 2022-05-12 | — | — | US | disclosed |
| CN-114072388-A | Plant growth regulator and method for promoting plant growth | 株式会社吴羽 | 2022-02-18 | — | — | CN | disclosed |
| US-20220031969-A1 | RESERVOIR FOR AN INHALATION DEVICE | SOFTHALE NV (BE) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629484-B2 | High pressure inhalation device | PSMD3, PSMC2, PSMD2 | NPY5R 1440/4885TMEM97 324/4885GAA 4721/4885 |
| US-12569629-B2 | Inhalation device system | VMA21, CRH, AVPR2 | NPY5R 532/4885TMEM97 337/4885GAA 2451/4885 |
| US-12576218-B2 | Valve | PSMD9, ATP6V0C, TMCO1 | NPY5R 4091/4885TMEM97 200/4885GAA 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.